sur ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics' new strategic plan for 2026-2028
On December 9, 2025, OSE Immunotherapeutics presented an ambitious strategic plan for the period 2026-2028. The company is focusing on four key areas to maximize value creation. First, the completion of the Phase 3 trial of Tedopi® in non-small cell lung cancer is planned, with analyses expected in 2026 and 2028. This project will require limited financial investment. Second, Lusvertikimab is slated for development for rare diseases, leveraging its intravenous formulation.
The company also plans to develop a subcutaneous version of Lusvertikimab for ulcerative colitis. Finally, OSE Immunotherapeutics intends to strengthen its scientific leadership through innovation and rigorous management of its intellectual property. A balanced financial strategy aims to limit shareholder dilution while securing diversified funding. A webinar is scheduled for December 10 to detail this plan to stakeholders.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ORPHAN SYNERGY EUROPE-PHARMA